Entrectinib

INN (International Nonproprietary Name)

🇺🇸 Also approved in the US (FDA)

ROZLYTREK — GENENTECH INC, approved 2023-10-20 (NDA218550).

Most reported adverse events (US / FAERS)

1,233 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

off label use

167

dizziness

149

death

134

disease progression

115

Medicines containing this active substance

1 medicines

Rozlytrek

Authorised

🇺🇸 Also approved in the US (FDA)

ROZLYTREK — GENENTECH INC, approved 2023-10-20 (NDA218550).

Most reported adverse events (US / FAERS)

1,233 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

off label use

167

dizziness

149

death

134

disease progression

115

taste disorder

70

drug ineffective

69

no adverse event

69

constipation

65

fatigue

62

blood creatinine increased

60

diarrhoea

59

nausea

58

renal impairment

57

weight increased

52

cardiac failure

47